Qingmu is an innovation driven pharmaceutical company
We have been operating for 12 years,the company specializes in R&D and manufacturing of generic APIs and advanced intermediates, and also provides CDMO/CMO service for small molecule chemical drugs.
About Us
Experience & trust built for 12 years
Sichuan Qingmu Pharmaceutical Co., Ltd., founded in May 2011, is a wholly-owned subsidiary of Chengdu Easton Biopharmaceuticals Co.,Ltd. (Sock code: 688513).
Qingmu is an innovation driven pharmaceutical company with primary strategic focus on the regulated market, the company speciallize in R&D and manufacturing of generic APIs and advanced intermediates, and also provides CDMO/CMO service for small molecule chemical drugs.
R & D
R & D Platform
Based on R&D concept “Green Chemistry “, Qingmu has gradually established key technical platforms such as asymmetric synthesis, transition metal catalysis (Cu, Fe, etc.), microchannel production, enzyme catalysis and drug crystallization process.
Manufacturing
Manufacturing System
Policy: People-oriented, health and safety, energy conservation and environmental protection, pollution prevention, full participation, sustainable development
Our News
News Center
Apalutamide API vs. Abiraterone Acetate: A Comparative Analysis
Bisoprolol: Mechanism of Action, Pharmacokinetics, and Clinical Applications
Axitinib Tablets: Uses and Side Effects
Dabigatran Etexilate: Redefining Anticoagulant Therapy
A Comparison Between Maropitant Citrate and Maropitant
Bisoprolol Fumarate vs. Newer Medications for Hypertension
The Comparison Between Sugammadex Sodium and Sugammadex
